Investor directory

3B Ventures

3B Ventures, founded in 2017 and based in Copenhagen, Denmark, operates as a traditional non-venture capital entity focused on fostering innovation. The company supports entrepreneurs who aim to create market-disrupting enterprises while addressing one or more of the Sustainable Development Goals established by the United Nations. By leveraging artificial intelligence and a data-driven approach, 3B Ventures identifies investment opportunities and selects startups based on extensive data points gathered from a global network of partners. The firm emphasizes a commitment to making a noticeable difference through its funding decisions, concentrating on technology companies primarily in the Nordic and Southeast Asian regions.
http://3bvc.com
https://crunchbase.com/organization/3b-ventures
https://linkedin.com/company/3b-ventures
https://pitchbook.com/profiles/investor/226214-11
https://twitter.com/3b_vc
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=574291302
https://www.privateequityinternational.com/database/#/profile?id=19078

Andrew Tan Yan Hoang

Fund Manager

1 past transactions

AnaCardio

Series A in 2022
AnaCardio is a clinical-stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company’s therapeutic drugs aim to enhance the contractility of the heart muscle through a unique mechanism involving a therapeutic peptide. This approach is designed to avoid common adverse effects associated with heart treatments, such as tachycardia, arrhythmia, ischemia, and hypotension. By improving cardiac output safely, AnaCardio's therapies have the potential to enhance organ function, boost quality of life, increase functional capacity, and reduce the risk of hospitalization and mortality in patients with heart failure.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.